首页> 外文期刊>Journal of Pharmacological and Toxicological Methods >Characterization of compound mechanisms and secondary activities by BioMAP analysis.
【24h】

Characterization of compound mechanisms and secondary activities by BioMAP analysis.

机译:通过BioMAP分析表征复合机制和二级活性。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Unexpected drug activities account for many of the failures of new chemical entities in clinical trials. These activities can be target-dependent, resulting from feedback mechanisms downstream of the primary target, or they can occur as a result of unanticipated secondary target(s). Methods that would provide rapid and efficient characterization of compounds with respect to a broad range of biological pathways and mechanisms relevant to human disease have the potential to improve preclinical and clinical success rates. METHODS: BioMAP assays containing primary human cells (endothelial cells and co-cultures with peripheral blood leukocytes) were stimulated in complex formats (specific combinations of inflammatory mediators) for 24 h in the presence or absence of test agents (drugs, experimental compounds, etc.). The levels of selected protein readouts (adhesion receptors, cytokines, enzymes, etc.) were measured and activity profiles (normalized data sets comprising BioMAP profiles) were generated for each test agent. The resulting profiles were compared by statistical methods to identify similarities and mechanistic insights. RESULTS: Compounds with known mechanisms including inhibitors of histamine H1 receptor, angiotensin converting enzyme, IkappaB kinase-2, beta2 adrenergic receptor and others were shown to generate reproducible and distinguishable BioMAP activity profiles. Similarities were observed between compounds targeting components within the same signal transduction pathway (e.g. NFkappaB), and also between compounds that share secondary targets (e.g. ibuprofen and FMOC-L-leucine, a PPARgamma agonist). DISCUSSION: Complex primary cell-based assays can be applied for detecting and distinguishing unexpected activities that may be of relevance to drug action in vivo. The ability to rapidly test compounds prior to animal or clinical studies may reduce the number of compounds that unexpectedly fail in preclinical or clinical studies.
机译:简介:药物意外活动导致了临床试验中新化学实体的许多失败。这些活动可能是依赖于目标的,是由于主要目标下游的反馈机制导致的,也可能是由于意外的次要目标而导致的。相对于与人类疾病相关的广泛的生物学途径和机制,能够提供快速,有效的化合物表征的方法,具有提高临床前和临床成功率的潜力。方法:在存在或不存在测试剂(药物,实验化合物等)的情况下,以复杂形式(炎性介质的特定组合)将包含原代人细胞(内皮细胞以及与外周血白细胞的共培养物)的BioMAP测定法刺激24小时)。测量所选蛋白质读数(粘附受体,细胞因子,酶等)的水平,并为每种测试试剂生成活性谱(包括BioMAP谱的标准化数据集)。通过统计方法对所得轮廓进行比较,以识别相似性和机理见解。结果:具有已知机制的化合物,包括组胺H1受体抑制剂,血管紧张素转化酶,IkappaB激酶-2,β2肾上腺素能受体等,已显示出可重现和可区分的BioMAP活性谱。在相同信号转导途径中靶向组分的化合物之间(例如NFkappaB)以及共享次级靶标的化合物(例如布洛芬和FMOC-L-亮氨酸(PPARγ激动剂))之间观察到相似性。讨论:复杂的基于原代细胞的分析可用于检测和区分可能与体内药物作用有关的意外活动。在动物或临床研究之前快速测试化合物的能力可以减少在临床前或临床研究中意外失败的化合物的数量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号